BMS-986143 is a potent, reversible inhibitor of the Bruton’s tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible drugs for oncology. The safety bar is much higher for inflammatory conditions, however, which led the BMS team to pursue reversible inhibitors. The two defined axial stereocenters of compounds [...]
< 1 minute read
Sep. 18, 2021
BMS-986143: An Oral Reversible Selective BTK Kinase Inhibitor
BMS-986143
oral reversible selective BTK kinase inhibitor related cmpds in dev. for inflamm. conditions from rational design of prior crystallized leads ACS Med. Chem. Lett., Sep. 22, 2020 Bristol Myers Squibb, Princeton, NJ